Moinzadeh Alireza, Libertino John A
Department of Urology, Lahey Clinic, Burlington, Massachusetts, USA.
J Urol. 2004 Feb;171(2 Pt 1):598-601. doi: 10.1097/01.ju.0000108842.27907.47.
We investigated the prognostic significance of venous tumor thrombus extension in patients with renal cell carcinoma with particular emphasis on 2 questions. Does the level of thrombus in the inferior vena cava (IVC) impact long-term survival? Is there a difference in long-term survival when tumor thrombus is in the renal vein versus the IVC for patients classified as T3b by 1997 TNM staging?
Between July 1970 and July 2000, 153 patients underwent surgical resection. Cancer specific survival was determined for different tumor thrombus levels in a retrospective fashion.
Mean followup was 60 months with a range of 12 to 221. Level of tumor thrombus was renal vein (in 46), level I (in 68), level II (in 17) and level III (in 22). No demographic differences existed between the different levels including gender, age, perinephric extension, Fuhrman grade, percentage of metastatic disease and tumor size (Fisher's exact test). Patients with evidence of nodal disease or metastasis at surgery were eliminated from cancer specific survival analysis. The overall 10-year cancer specific survival for patients was 30%, 19% and 29% for level I, II and III, respectively. Patient survival at 5 and 10 years was not significantly different between the 3 IVC levels (p = 0.48). Ten-year survival of patients with renal vein involvement (66%) versus level I (29%) was significantly different (p = 0.0001).
The level of tumor thrombus in the IVC does not significantly effect long-term survival. Ten-year survival of patients classified as T3b is statistically different for patients having tumor thrombus in the renal vein compared to level I. Combining these 2 groups as T3b by the 1997 TNM staging may need to be reevaluated.
我们研究了肾细胞癌患者静脉肿瘤血栓延伸的预后意义,特别关注两个问题。下腔静脉(IVC)内血栓水平是否影响长期生存?对于根据1997年TNM分期归类为T3b的患者,肿瘤血栓位于肾静脉与位于下腔静脉时,长期生存是否存在差异?
1970年7月至2000年7月期间,153例患者接受了手术切除。以回顾性方式确定不同肿瘤血栓水平的癌症特异性生存率。
平均随访时间为60个月,范围为12至221个月。肿瘤血栓水平为肾静脉(46例)、I级(68例)、II级(17例)和III级(22例)。不同水平之间在人口统计学方面无差异,包括性别、年龄、肾周延伸、Fuhrman分级、转移疾病百分比和肿瘤大小(Fisher精确检验)。手术时有淋巴结疾病或转移证据的患者被排除在癌症特异性生存分析之外。I级、II级和III级患者的总体10年癌症特异性生存率分别为30%、19%和29%。3种下腔静脉水平患者的5年和10年生存率无显著差异(p = 0.48)。肾静脉受累患者的10年生存率(66%)与I级患者(29%)有显著差异(p = 0.0001)。
下腔静脉内肿瘤血栓水平对长期生存无显著影响。对于归类为T3b的患者,肿瘤血栓位于肾静脉的患者与I级患者相比,10年生存率在统计学上有差异。1997年TNM分期将这两组合并为T3b可能需要重新评估。